^
Association details:
| Biomarker: | FLT3 N676T |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | FF-10101 (FLT3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FF-10101 Retains Potent Inhibitory Activities Against Resistant Mutations to FLT3 Inhibitors, Newly Identified in Random Mutagenesis Screen
Published date:
11/06/2019
Excerpt:
In FLT3-ITD+N676T-expressing 32D cells, inhibitory activities of quizartinib and midostaurin were decreased by 11 and 15-fold (GI50, 6.6 nM and 83 nM, respectively), while FF-10101 (GI50, 0.73 nM), gilteritinib (GI50, 6.6 nM) and crenolanib (GI50, 19 nM) retained potency.
DOI:
https://doi.org/10.1182/blood-2019-124632
